T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies
Pharmaceutical Technology
JANUARY 10, 2023
The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.
Let's personalize your content